Titan Pharmaceuticals Reports Positive Initial Results Of Probuphine® Relaunchfinance.yahoo.com • about 5 years ago---
- SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 /PRNewswire/ -- Titan Pharmaceuticals,
Inc. (TTNP), today provided an update on the U.S. commercial relaunch of Probuphine
(buprenorphine) implant, its unique six-month treatment for Opioid Use Disorder
(OUD).
- The U.S. Food and Drug Administration (FDA) approved Probuphine in May 2016, and
it is the first and only buprenorphine implant available for the maintenance treatment
of opioid is an implant that contains the medicine buprenorphine.
- 'Call your healthcare provider right away if: PROBUPHINE sticks out of the skin
or comes out by itself You have bleeding or symptoms of infection at the site after
insertion or removal, including excessive or worsening itching, pain, irritation,
redness, or swelling You have numbness or weakness in your arm after the insertion
or removal procedure You have weakness or numbness in your arm, or shortness of
breath Because of the risk of complications of, migration, protrusion, expulsion
and nerve injury with insertion and removal of PROBUPHINE, it is only available
through a restricted program called the PROBUPHINE REMS Program.'
- 'Before starting Probuphine tell your doctor about all of your medical conditions,
including: Trouble breathing or lung problems, an enlarged prostate gland (men),
a head injury or brain problem, problems urinating, a curve in your spine that affects
your breathing, liver problems, gallbladder or adrenal gland problems, Addison''s
disease, low thyroid hormone levels (hypothyroidism), a history of alcoholism, a
history of keloid formation, connective tissue disease (such as scleroderma), or
history of MRSA infections, mental problems such as hallucinations, an allergy to
numbing medicines or medicines used to clean your skin, are pregnant or plan to
become pregnant or are breastfeeding or plan to breastfeed.'
- Approved by the U.S. Food and Drug Administration in May 2016, Probuphine is the
first and only commercialized treatment of opioid dependence to provide continuous,
around-the-clock blood levels of buprenorphine for six months following a single
procedure.